

Ian N Bruce

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8639870/publications.pdf>

Version: 2024-02-01

292
papers

32,154
citations

12328

69
h-index

4431

172
g-index

300
all docs

300
docs citations

300
times ranked

31709
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007, 447, 661-678.	27.8	8,895
2	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
3	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	21.4	1,298
4	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	27.8	737
5	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 382, 211-221.	27.0	725
6	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2074-2082.	0.9	578
7	A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci. <i>PLoS Genetics</i> , 2008, 4, e1000041.	3.5	572
8	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
9	Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. <i>Nature</i> , 2007, 450, 887-892.	27.8	493
10	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 222-231.	18.7	396
11	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
12	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
13	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , 2007, 39, 1431-1433.	21.4	361
14	Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. <i>Nature Genetics</i> , 2010, 42, 996-999.	21.4	334
15	Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003, 48, 3159-3167.	6.7	327
16	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
17	Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: Further support that PTPN22 is an autoimmunity gene. <i>Arthritis and Rheumatism</i> , 2005, 52, 1694-1699.	6.7	266
18	Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. <i>Arthritis and Rheumatism</i> , 2007, 56, 265-273.	6.7	262

#	ARTICLE	IF	CITATIONS
19	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 57, 972-979.	6.7	252
20	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e208-e219.	3.9	250
21	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	1.9	247
22	“Not only” but also™: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005, 44, 1492-1502.	1.9	244
23	Systemic Lupus Erythematosus. <i>Circulation</i> , 2004, 110, 399-404.	1.6	242
24	Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 529-535.	0.9	240
25	Atherosclerosis in rheumatoid arthritis: is it all about inflammation?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 390-400.	8.0	221
26	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018, 7, 356.	2.4	215
27	Clinical applications of machine learning algorithms: beyond the black box. <i>BMJ: British Medical Journal</i> , 2019, 364, l886.	2.3	213
28	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011, 50, 982-988.	1.9	155
29	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 257-278.	1.9	154
30	Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2010, 62, 881-887.	3.4	153
31	Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 672-676.	0.9	149
32	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	12.8	149
33	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
34	Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1726-1732.	0.9	132
35	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 768-779.	0.9	128
36	Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. <i>Arthritis Care and Research</i> , 2012, 64, 132-137.	3.4	126

#	ARTICLE	IF	CITATIONS
37	Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3705-3709.	6.7	122
38	The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 352-361.	3.4	118
39	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
40	Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 187-195.	1.5	109
41	Anti-C1q antibodies in systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 42-49.	1.6	106
42	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1641-1644.	0.9	103
43	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2012, 51, 634-643.	1.9	102
44	The prevalence and incidence of biopsy-proven lupus nephritis in the UK: Evidence of an ethnic gradient. <i>Arthritis and Rheumatism</i> , 2006, 54, 2963-2969.	6.7	101
45	Factors associated with fatigue in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 379-381.	0.9	99
46	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
47	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
48	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 4113-4119.	6.7	96
49	Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. <i>Lupus</i> , 2011, 20, 250-255.	1.6	96
50	Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006, 54, 3300-3305.	6.7	93
51	Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 677-682.	0.9	92
52	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 227-234.	2.0	91
53	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
54	Modifiable risk factors for RA: prevention, better than cure?. <i>Rheumatology</i> , 2012, 51, 499-512.	1.9	90

#	ARTICLE	IF	CITATIONS
55	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 50-6.	2.0	89
56	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005, 32, 1467-72.	2.0	87
57	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 54-59.	0.9	86
58	Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. <i>Lupus</i> , 2007, 16, 731-735.	1.6	85
59	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
60	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
61	Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. <i>Lupus</i> , 2016, 25, 699-709.	1.6	82
62	Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. <i>BMJ Open</i> , 2019, 9, e025687.	1.9	81
63	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1007-1011.	0.9	78
64	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
65	25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 544-551.	1.9	77
66	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77
67	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1437-1449.	5.6	77
68	Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1144-1150.	0.9	75
69	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	75
70	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
71	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
72	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70

#	ARTICLE	IF	CITATIONS
73	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. <i>Pharmacogenomics</i> , 2011, 12, 815-826.	1.3	69
74	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. <i>Rheumatology</i> , 2015, 54, 1780-1791.	1.9	69
75	Evidence to support <i>IL-13</i> as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1016-1019.	0.9	68
76	MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. <i>Pharmacogenomics Journal</i> , 2013, 13, 137-147.	2.0	67
77	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008, 58, 1784-1788.	6.7	66
78	Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19-associated Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 2003, 36, e100-e106.	5.8	65
79	Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3596-3602.	6.7	65
80	HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 807-811.	0.9	64
81	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.9	64
82	Variants in <i>RUNX3</i> Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1224-1231.	6.7	63
83	Indications for IVIG in rheumatic diseases. <i>Rheumatology</i> , 2015, 54, 383-391.	1.9	63
84	The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. <i>European Journal of Clinical Investigation</i> , 1994, 24, 759-765.	3.4	62
85	High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. <i>Lupus</i> , 2007, 16, 387-393.	1.6	62
86	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	2.7	62
87	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	56
88	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 823-838.	3.3	56
89	The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 985-989.	6.7	56
90	Therapy Insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 423-430.	3.3	55

#	ARTICLE	IF	CITATIONS
91	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
92	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
93	The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2010, 37, 2273-2279.	2.0	54
94	Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus. <i>Scientific Reports</i> , 2016, 6, 22341.	3.3	54
95	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. <i>Lupus</i> , 2017, 26, 1051-1059.	1.6	52
96	Vitamin D and systemic lupus erythematosus - The hype and the hope. <i>Autoimmunity Reviews</i> , 2018, 17, 19-23.	5.8	52
97	Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. <i>Lupus Science and Medicine</i> , 2016, 3, e000143.	2.7	50
98	Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 934-940.	0.9	50
99	BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 873-876.	0.9	49
100	25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	3.4	49
101	Individuals living with lupus: findings from the LUPUS UK Members Survey 2014. <i>Lupus</i> , 2018, 27, 681-687.	1.6	49
102	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
103	Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 131-142.	5.6	47
104	SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 961-967.	0.9	45
105	Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2014, 66, 1374-1379.	3.4	45
106	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 1505-1513.	3.4	45
107	A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. <i>Rheumatology</i> , 2016, 55, 382-384.	1.9	45
108	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 6-9.	0.9	44

#	ARTICLE	IF	CITATIONS
109	Atherogenesis and autoimmune disease: the model of lupus. <i>Lupus</i> , 2005, 14, 687-690.	1.6	43
110	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	1.9	43
111	An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 1459-1465.	1.6	42
112	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
113	Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. <i>Arthritis Research and Therapy</i> , 2018, 20, 173.	3.5	41
114	Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 15-19.	0.9	40
115	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
116	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
117	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1350-1354.	0.9	39
118	Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 128-135.	3.4	39
119	Current challenges in the development of new treatments for lupus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 729-735.	0.9	39
120	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
121	Brief Report: Shortened Telomere Length in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 2013, 65, 1319-1323.	6.7	38
122	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. <i>Lancet Rheumatology, The</i> , 2020, 2, e99-e109.	3.9	38
123	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.9	38
124	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
125	Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 870-874.	0.9	36
126	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	2.0	36

#	ARTICLE	IF	CITATIONS
127	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2199-2203.	0.9	36
128	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	3.9	36
129	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
130	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 19-23.	4.7	34
131	Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. <i>Current Opinion in Lipidology</i> , 2008, 19, 338-343.	2.7	34
132	Decreased live births in women with systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1068-1072.	3.4	34
133	Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease. <i>BBA Clinical</i> , 2017, 7, 16-22.	4.1	34
134	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34
135	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e282-e292.	3.9	34
136	Biomarkers of oxidant stress, insulin sensitivity and endothelial activation in rheumatoid arthritis: a cross-sectional study of their association with accelerated atherosclerosis. <i>BMC Research Notes</i> , 2009, 2, 83.	1.4	32
137	SLE and pregnancy: the potential role for regulatory T cells. <i>Nature Reviews Rheumatology</i> , 2011, 7, 124-128.	8.0	32
138	Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R81.	3.5	31
139	The Metabolic Syndrome in Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 81-97.	1.9	31
140	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 684-690.	0.9	31
141	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
142	Reduction of long-term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2011, 63, 945-952.	3.4	30
143	Brief Report: Vitamin D Deficiency Is Associated With Endothelial Dysfunction and Increases Type I Interferon Gene Expression in a Murine Model of Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 2929-2935.	5.6	30
144	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003, 30, 288-91.	2.0	30

#	ARTICLE	IF	CITATIONS
145	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	3.8	29
146	Rheumatoid arthritis reprograms circadian output pathways. <i>Arthritis Research and Therapy</i> , 2019, 21, 47.	3.5	29
147	Golimumab for the Treatment of Psoriatic Arthritis. <i>Pharmacoeconomics</i> , 2012, 30, 257-270.	3.3	28
148	American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2014, 41, 875-880.	2.0	28
149	Cognitive dysfunction and functional magnetic resonance imaging in systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 1239-1247.	1.6	28
150	Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. <i>Lupus</i> , 2014, 23, 819-824.	1.6	27
151	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
152	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. <i>Arthritis Research and Therapy</i> , 2011, 13, R159.	3.5	26
153	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , 2018, 70, 98-103.	3.4	26
154	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor- α treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	1.9	26
155	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
156	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. <i>Rheumatology</i> , 2021, 60, 3747-3759.	1.9	26
157	Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. <i>Lupus Science and Medicine</i> , 2017, 4, e000173.	2.7	25
158	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
159	Regulatory T cells in Systemic Lupus Erythematosus and Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 588-595.	1.2	24
160	The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. <i>Lupus</i> , 2014, 23, 273-283.	1.6	23
161	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
162	An audit of ANCA in routine clinical practice. <i>Postgraduate Medical Journal</i> , 1995, 71, 605-612.	1.8	22

#	ARTICLE	IF	CITATIONS
163	Vitamin D treatment for connective tissue diseases: hope beyond the hype?. <i>Rheumatology</i> , 2017, 56, 178-186.	1.9	22
164	QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018, 5, e000272.	2.7	22
165	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
166	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	1.9	22
167	Re-evaluation of biologic therapies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2010, 22, 273-277.	4.3	21
168	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
169	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. <i>RMD Open</i> , 2020, 6, e001257.	3.8	21
170	Genetic epidemiology: systemic lupus erythematosus. <i>Arthritis Research</i> , 2001, 3, 331.	2.0	20
171	Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1390-1393.	0.9	20
172	Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 384-396.	3.4	20
173	Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. <i>Arthritis Research and Therapy</i> , 2019, 21, 147.	3.5	20
174	Cardiovascular risk factors in inflammatory arthritis. <i>Current Opinion in Lipidology</i> , 2011, 22, 296-301.	2.7	19
175	Association of morbid obesity with disability in early inflammatory polyarthritis: Results from the Norfolk Arthritis Register. <i>Arthritis Care and Research</i> , 2013, 65, 122-126.	3.4	19
176	Improving cardiovascular outcomes in rheumatic diseases: Therapeutic potential of circulating endothelial progenitor cells. , 2014, 142, 231-243.		19
177	Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors. <i>Lupus Science and Medicine</i> , 2018, 5, e000267.	2.7	19
178	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). <i>Clinical Immunology</i> , 2020, 214, 108375.	3.2	19
179	Systemic lupus erythematosus, eosinophilic vasculitis and acalculous cholecystitis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 792-795.	0.7	18
180	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	2.7	18

#	ARTICLE	IF	CITATIONS
181	Health-related quality of life, smoking and carotid atherosclerosis in white British women with systemic lupus erythematosus. <i>Lupus</i> , 2010, 19, 231-238.	1.6	17
182	Clinical trials in lupus: what have we learned so far?. <i>Rheumatology</i> , 2010, 49, 1025-1027.	1.9	17
183	Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2012, 39, 735-742.	2.0	17
184	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
185	Endothelial progenitor cells: a new player in lupus?. <i>Arthritis Research and Therapy</i> , 2012, 14, 203.	3.5	16
186	Evaluation of carotid plaque inflammation in patients with active rheumatoid arthritis using 18F-fluorodeoxyglucose PET-CT and MRI: a pilot study. <i>Lancet, The</i> , 2015, 385, S91.	13.7	16
187	Psoriatic Arthritis. <i>BioDrugs</i> , 1998, 9, 271-278.	4.6	15
188	Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008, 58, 1789-1795.	6.7	15
189	Systemic lupus erythematosus, regulatory T cells and pregnancy. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 635-648.	3.0	15
190	Investigation of IL1, VEGF, PPARC and MEFV genes in psoriatic arthritis susceptibility: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 313-314.	0.9	15
191	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 492-500.	2.0	15
192	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019, 6, e000342.	2.7	15
193	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.9	15
194	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
195	Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. <i>Rheumatology</i> , 2022, 61, 4006-4015.	1.9	14
196	Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 225-33.	0.8	14
197	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 765-777.	1.4	14
198	Risk factors for coronary heart disease in connective tissue diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 145-153.	2.7	13

#	ARTICLE	IF	CITATIONS
199	The BILAG-2004 systems tallyâ€”a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012, 51, 2099-2105.	1.9	13
200	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales. <i>Clinical Rheumatology</i> , 2012, 31, 1005-1012.	2.2	13
201	Cardiovascular risk and inflammatory rheumatic diseases. <i>Clinical Medicine</i> , 2013, 13, 395-397.	1.9	13
202	Cardiovascular risk and its modification in patients with connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 81-94.	3.3	12
203	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	1.9	12
204	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
205	What Does it Mean to be a British Isles Lupus Assessment Groupâ€”Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. <i>Arthritis and Rheumatology</i> , 2021, 73, 2059-2068.	5.6	12
206	Differential levels of IFNÎ± subtypes in autoimmunity and viral infection. <i>Cytokine</i> , 2021, 144, 155533.	3.2	12
207	The Effect of Type 1 IFN on Human Aortic Endothelial Cell Function <i>In Vitro</i> : Relevance to Systemic Lupus Erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 404-412.	1.2	11
208	Mapping the disease-specific LupusQoL to the SF-6D. <i>Quality of Life Research</i> , 2015, 24, 1749-1758.	3.1	11
209	Drug efflux transporters in rheumatoid arthritis: Comment on the article by Kremer. <i>Arthritis and Rheumatism</i> , 2005, 52, 670-670.	6.7	10
210	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , 2021, 17, 307-308.	8.0	10
211	Subclinical atherosclerosis in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2004, 31, 841-3.	2.0	10
212	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€”FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
213	The challenges in data integration â€” heterogeneity and complexity in clinical trials and patient registries of Systemic Lupus Erythematosus. <i>BMC Medical Research Methodology</i> , 2020, 20, 164.	3.1	9
214	Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Rheumatology</i> , The, 2021, 3, e101-e110.	3.9	9
215	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
216	Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 1822-1828.	3.4	9

#	ARTICLE	IF	CITATIONS
217	Improved wrist pannus volume measurement from contrast-enhanced MRI in rheumatoid arthritis using shuffle transform. <i>Magnetic Resonance Imaging</i> , 2007, 25, 110-116.	1.8	8
218	Cardiovascular Outcomes in Systemic Lupus Erythematosus: Big Studies for Big Questions. <i>Journal of Rheumatology</i> , 2009, 36, 467-469.	2.0	8
219	Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 65-78.	3.4	8
220	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
221	Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE—data from the BSR audit of systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 1474-1479.	1.9	8
222	The effects of disease activity on neuronal and behavioural cognitive processes in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 61, 195-204.	1.9	8
223	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). <i>Lupus Science and Medicine</i> , 2021, 8, e000513.	2.7	8
224	Clinical Markers, Metrics, Indices, and Clinical Trials. , 2019, , 614-630.		7
225	BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK. <i>Rheumatology</i> , 2021, 60, 1480-1490.	1.9	7
226	Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. <i>Lupus Science and Medicine</i> , 2021, 8, e000459.	2.7	7
227	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021, 8, e000433.	2.7	7
228	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
229	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
230	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	1.9	6
231	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1517-1523.	0.9	5
232	Generating evidence to inform health technology assessment of treatments for SLE: a systematic review of decision-analytic model-based economic evaluations. <i>Lupus Science and Medicine</i> , 2020, 7, e000350.	2.7	5
233	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3262-3267.	1.9	5
234	Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical Evaluation of Novel Targets in RA (PREVeNT-RA) Cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 210.	3.5	5

#	ARTICLE	IF	CITATIONS
235	Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000584.	2.7	5
236	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 21-30.	0.1	4
237	Longitudinal analysis of urinary proteins in lupus nephritis – A pilot study. <i>Clinical Immunology</i> , 2022, 236, 108948.	3.2	4
238	Evaluation of non-contrast MRI biomarkers in lupus nephritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 954-958.	0.8	4
239	Coronary heart disease (CHD) in lupus: round up the usual suspects?. <i>Lupus</i> , 2004, 13, 557-560.	1.6	3
240	Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018, 57, .	1.9	3
241	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	3.9	3
242	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
243	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. <i>Arthritis Research and Therapy</i> , 2021, 23, 203.	3.5	3
244	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	3
245	The effects of disease activity, inflammation, depression and cognitive fatigue on resting state fMRI in systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, S139-S147.	1.9	3
246	Immune gene expression and functional networks in distinct lupus nephritis classes. <i>Lupus Science and Medicine</i> , 2022, 9, e000615.	2.7	3
247	Investigation of association of the DLG5 gene with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 273-274.	0.9	2
248	Vitamin D in systemic lupus erythematosus: potential beyond bone health. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 297-309.	0.3	2
249	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	1.9	2
250	Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
251	Pregnancy outcomes of a joint obstetric and rheumatology clinic in a tertiary centre: a 2-year retrospective study of 98 pregnancies. <i>Rheumatology Advances in Practice</i> , 2022, 6, rak026.	0.7	2
252	Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. <i>Rheumatology</i> , 0, , .	1.9	2

#	ARTICLE	IF	CITATIONS
253	Efficiency in follow-up immunology testing for patients with connective tissue diseases and vasculitis. <i>Clinical Medicine</i> , 2011, 11, 632-633.	1.9	1
254	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017, 19, 287.	3.5	1
255	Quality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. <i>Rheumatology</i> , 2018, 57, .	1.9	1
256	A molecular taxonomy for systemic autoimmune rheumatic diseases (SARDs): learning lessons from oncology?. <i>Rheumatology</i> , 2020, 59, 2193-2194.	1.9	1
257	Effectiveness of rituximab in the treatment of neuro-psychiatric SLE: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2021, 60, .	1.9	1
258	Clinical features of psoriatic arthritis. , 2011, , 1183-1193.e2.		1
259	Clinical features of psoriatic arthritis. , 2015, , 989-997.		1
260	Systemic lupus erythematosus: a pragmatic guide to current management: IP63. Assessment and Management of Systemic Lupus Erythematosus in the Routine Clinic Setting. <i>Rheumatology</i> , 2011, 50, iii16-iii16.	1.9	0
261	Anti-Citrullinated Protein Antibody Status in the General Population and as a Predictor of Future Inflammatory Polyarthritis: The Epic-2-Noar Study. <i>Rheumatology</i> , 2015, , .	1.9	0
262	Characterizing Pregnancy Vascular Changes in SLE. <i>Rheumatology</i> , 0, , .	1.9	0
263	Vitamin D Improves Endothelial Function and Endothelial Repair in Systemic Lupus Erythematosus. <i>Rheumatology</i> , 2015, , .	1.9	0
264	Acute Necrotizing Pancreatitis in SLE: A Case Report and Literature Review. <i>Rheumatology</i> , 2015, , .	1.9	0
265	Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor- α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, , .	1.9	0
266	A Stratified Medicine Approach to Drug Response in Systemic Lupus Erythematosus. <i>Rheumatology</i> , 2016, , .	1.9	0
267	Medication-related side effects in vasculitis: a patient self-report survey of awareness and reported uptake of protective therapy. <i>Rheumatology</i> , 2016, 55, 185-186.	1.9	0
268	THE EFFECTS OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS ON ATTENTION. <i>Rheumatology</i> , 2017, 56, .	1.9	0
269	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
270	Cross sectional validation of BILAG2004-Pregnancy Index. <i>Rheumatology</i> , 2018, 57, .	1.9	0

#	ARTICLE	IF	CITATIONS
271	137â€fPredictors of hypogammaglobulinaemia in rituximab treated systemic lupus erythematosus and vasculitis patients. Rheumatology, 2018, 57, .	1.9	0
272	O21â€fBILAG2004-Pregnancy index is sensitive to change. Rheumatology, 2018, 57, .	1.9	0
273	O08â€fSymptoms in first degree relatives of patients with rheumatoid arthritis: evaluation of data from the symptoms in persons at risk of rheumatoid arthritis questionnaire. Rheumatology, 2019, 58, .	1.9	0
274	233â€fEnhancing quality improvement capacity through the British Society for Rheumatologyâ€™s multi-region audit into the management of adults with systemic lupus erythematosus. Rheumatology, 2019, 58, .	1.9	0
275	098â€fQuality improvement to halve non-adherence to methotrexate. Rheumatology, 2019, 58, .	1.9	0
276	242â€fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	1.9	0
277	145â€fThe British Society for Rheumatologyâ€™s Choosing Wisely UK recommendations. Rheumatology, 2019, 58, .	1.9	0
278	FRIO188â€f...EARLY RENAL IMPROVEMENTS FOLLOWING RITUXIMAB IN LUPUS NEPHRITIS. , 2019, , .		0
279	FRIO173â€f...HOW WELL DO CLINICAL TRIALS REPRESENT REAL WORLD LUPUS NEPHRITIS PATIENTS?. , 2019, , .		0
280	P175â€fMASTERPLANS: prediction of response to rituximab in SLE using a validated two-score system for interferon. Rheumatology, 2020, 59, .	1.9	0
281	P169â€fA validated two-score system for interferon is a predictor of response to rituximab in SLE. Rheumatology, 2021, 60, .	1.9	0
282	P096â€fPregnancy outcomes in women attending a joint obstetric and rheumatology clinic in a tertiary centre over a 2-year period. Rheumatology, 2021, 60, .	1.9	0
283	P166â€fMultimorbidity in SLE, a barrier to clinical trial eligibility: results from the BILAG-BR. Rheumatology, 2021, 60, .	1.9	0
284	P170â€fThe validity and utility of the SLE-keyÂ® rule-out serological test when applied in a selected cohort of patients with SLE and other connective tissue diseases. Rheumatology, 2021, 60, .	1.9	0
285	O19â€fEasy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004. Rheumatology, 2021, 60, .	1.9	0
286	1124â€f...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
287	1107â€f...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
288	Probabilistic Approaches to Overcome Content Heterogeneity in Data Integration: A Study Case in Systematic Lupus Erythematosus. Studies in Health Technology and Informatics, 2020, 270, 387-391.	0.3	0

#	ARTICLE	IF	CITATIONS
289	P039â€fSeptic arthritis caused by Mycoplasma hominis in a patient with systemic lupus erythematosus. Rheumatology, 2022, 61, .	1.9	0
290	P240â€fPredictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: a systematic review update. Rheumatology, 2022, 61, .	1.9	0
291	P068â€fMonitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. Rheumatology, 2022, 61, .	1.9	0
292	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0